Evrópusambandið - eistneska - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - seedetraktist esinevad stromaal-kasvajad - antineoplastilised ained - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Evrópusambandið - eistneska - EMA (European Medicines Agency)

eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Eistland - eistneska - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - mitomütsiin - intravesikaallahuse pulber ja lahusti - 20mg 6tk; 20mg 4tk; 20mg 5tk

Evrópusambandið - eistneska - EMA (European Medicines Agency)

baxter holding b.v. - doksorubitsiini vesinikkloriid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastilised ained - caelyx pegylated liposomal on näidatud:kui monotherapy patsientidel metastaatilise rinnavähi, kus on suurem südame riski;ravi kaugelearenenud munasarja vähk naistel, kes ei ole suutnud esimese-line platinum põhineva keemiaravi raviskeemi;koos bortezomib ravi järk-järgulise hulgimüeloom patsientidel, kes on saanud vähemalt ühe eelneva ravi ja kes on juba läbinud või on sobimatud luuüdi siirdamine;raviks aids-iga seotud kaposi on sarkoom (ks) patsientidel, kellel on madal cd4 loeb (.

Evrópusambandið - eistneska - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastilised ained - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Eistland - eistneska - Ravimiamet

accord healthcare b.v. - mitomütsiin - intravesikaal-/süstelahuse pulber - 10mg 1tk; 10mg 5tk

Eistland - eistneska - Ravimiamet

accord healthcare b.v. - mitomütsiin - intravesikaal-/süstelahuse pulber - 2mg 10tk; 2mg 5tk

Eistland - eistneska - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - mitomütsiin - intravesikaallahuse pulber ja lahusti - 40mg 4tk; 40mg 5tk

Eistland - eistneska - Ravimiamet

pfizer europe ma eeig - tsütarabiin - süstelahuse pulber - 1000mg 1tk

Eistland - eistneska - Ravimiamet

pfizer europe ma eeig - tsütarabiin - süstelahuse pulber ja lahusti - 500mg 1tk